ArticleMolecular medicine (Cambridge, Mass.)2021

An mRNA assay system demonstrates proteasomal-specific degradation contributes to cardiomyopathic phospholamban null mutation.

Eduarde Rohner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.